CA2827373C - Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea - Google Patents

Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea Download PDF

Info

Publication number
CA2827373C
CA2827373C CA2827373A CA2827373A CA2827373C CA 2827373 C CA2827373 C CA 2827373C CA 2827373 A CA2827373 A CA 2827373A CA 2827373 A CA2827373 A CA 2827373A CA 2827373 C CA2827373 C CA 2827373C
Authority
CA
Canada
Prior art keywords
cream
oxymetazoline
pharmaceutically acceptable
acid
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2827373A
Other languages
English (en)
French (fr)
Other versions
CA2827373A1 (en
Inventor
Stuart D. Shanler
Christopher Powala
Original Assignee
EPI Health LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EPI Health LLC filed Critical EPI Health LLC
Publication of CA2827373A1 publication Critical patent/CA2827373A1/en
Application granted granted Critical
Publication of CA2827373C publication Critical patent/CA2827373C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
CA2827373A 2011-02-15 2012-02-14 Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea Active CA2827373C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161443210P 2011-02-15 2011-02-15
US61/443,210 2011-02-15
PCT/US2012/025068 WO2012112566A1 (en) 2011-02-15 2012-02-14 Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea

Publications (2)

Publication Number Publication Date
CA2827373A1 CA2827373A1 (en) 2012-08-23
CA2827373C true CA2827373C (en) 2019-05-14

Family

ID=45757218

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2827373A Active CA2827373C (en) 2011-02-15 2012-02-14 Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea

Country Status (11)

Country Link
US (4) US20120208858A1 (https=)
EP (2) EP3578178B1 (https=)
JP (3) JP6225030B2 (https=)
KR (2) KR20190114010A (https=)
CN (2) CN103458897A (https=)
AU (3) AU2012217858A1 (https=)
BR (1) BR112013020770A2 (https=)
CA (1) CA2827373C (https=)
ES (1) ES2742273T3 (https=)
RU (1) RU2648439C2 (https=)
WO (1) WO2012112566A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
BR112013020770A2 (pt) 2011-02-15 2019-08-27 Allergan, Inc. composições de creme farmacêutico de oximetazolina para tratamento de sintomas de rosácea
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
JP6174579B2 (ja) * 2011-08-04 2017-08-02 オメロス コーポレーション 安定な注射用抗炎症性溶液
MX357635B (es) 2011-09-20 2018-07-17 Allergan Inc Composiciones y metodos para el tratamiento de presbicia, hipermetropia leve, y astigmatismo irregular.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
FR3000395A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
AU2014212275B2 (en) 2013-02-01 2018-09-06 Ocuphire Pharma, Inc. Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
DK2950648T3 (da) 2013-02-01 2019-12-02 Ocuphire Pharma Inc Vandige oftalmiske opløsninger af phentolamin og medicinske anvendelser deraf
WO2015062611A1 (en) * 2013-10-28 2015-05-07 Astion Pharma A/S Compositions for dermatological use
AU2015252947B2 (en) * 2014-05-01 2020-07-09 Anterios, Inc. Demonstrable efficacy across or within patient populations
MX379253B (es) 2014-06-11 2025-03-11 Epi Health Llc Formulaciones de oximetazolina estabilizadas y sus usos.
WO2017049148A1 (en) * 2015-09-17 2017-03-23 June Jacobs Laboratiories, Llc Compositions and methods for the treatment and prevention of radiation dermatitis
EP3476393A4 (en) * 2016-06-28 2019-07-17 Doris Maria Hexsel USE OF AN ACTIVE AGENT FOR THE TREATMENT OF TELANGIEKTATISCHEM MELASMA
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EA202090763A1 (ru) * 2017-11-15 2020-08-03 Борис Славинович ФАРБЕР Фармацевтическая композиция для стимуляции деления стволовых клеток и подавления вирулентности бактерий
MX368750B (es) * 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
EP3866790A4 (en) 2018-10-15 2022-08-03 Ocuphire Pharma, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES
CA3116589A1 (en) 2018-10-26 2020-04-30 Ocuphire Pharma, Inc. Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
AU2019390704A1 (en) * 2018-11-26 2021-06-03 Cellix Bio Private Limited Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases
CN111840287A (zh) * 2019-04-30 2020-10-30 健艾仕生物医药有限公司 化合物在治疗炎症引起的自身免疫性皮肤病中的应用
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
KR102633256B1 (ko) * 2021-10-08 2024-02-05 (주)우리스마트바이오 참당귀 추출물을 이용한 피부개선용 화장품 조성물, 이를 포함한 피부개선용 화장품 및 피부개선용 화장품 제조방법
WO2023133199A1 (en) * 2022-01-05 2023-07-13 Asymmetric Therapeutics, Llc Methods and compositions for treatment of cutaneous proliferative disorders and other skin conditions
US20240423959A1 (en) * 2022-06-21 2024-12-26 Jjr&D, Llc Topical benzimidazole formulations and methods for use in treating inflammatory dermatoses

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3147275A (en) 1964-09-01 Nh-cha
US8093293B2 (en) * 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US6433024B1 (en) 2000-05-08 2002-08-13 Karl F. Popp Topical anti-acne composition
KR100898879B1 (ko) 2000-08-16 2009-05-25 돌비 레버러토리즈 라이쎈싱 코오포레이션 부수 정보에 응답하여 하나 또는 그 이상의 파라메터를변조하는 오디오 또는 비디오 지각 코딩 시스템
US6479060B1 (en) * 2001-09-04 2002-11-12 Healthpoint, Ltd. Elegant hydrogenated castor oil ointments
US6824786B2 (en) 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US6573301B1 (en) 2002-04-23 2003-06-03 Bradley Pharmaceuticals, Inc. Carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
JP4955543B2 (ja) * 2004-05-25 2012-06-20 サンズローザ ファーマシューティカル ディヴェロップメント インコーポレイテッド 炎症性皮膚疾患を治療又は予防するための化合物、製剤及び方法
CN101166535A (zh) 2005-03-15 2008-04-23 坎皮纳荷兰控股有限责任公司 乳蛋白的皮肤病学应用
JP5388568B2 (ja) * 2005-03-30 2014-01-15 ルバンス セラピュティックス インク． ざ瘡を治療するための組成物及び方法
KR101314689B1 (ko) 2005-06-29 2013-10-07 디에스엠 아이피 어셋츠 비.브이. 아이소플라본의 나노입자를 포함하는 국소용 조성물
WO2007103687A2 (en) * 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
US20080031979A1 (en) * 2006-08-04 2008-02-07 Claude Saliou Use of extracts for the treatment of viral disorders
RU2310439C1 (ru) * 2006-10-05 2007-11-20 Закрытое акционерное общество Фармацевтическое научно-производственное предприятие "Ретиноиды" (ЗАО "Ретиноиды") Мазевая акарицидная композиция и способ лечения демодекоза и сопутствующих ему заболеваний
US9511016B2 (en) * 2007-06-12 2016-12-06 Epicentrx, Inc. Topical composition for treating pain
US20090061020A1 (en) 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
JP5670196B2 (ja) 2007-11-16 2015-02-18 バイセプト セラピューティクス、インク． 紫斑を治療する組成物および方法
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
CA2779063A1 (en) 2009-10-26 2011-05-05 Galderma Pharma S.A. Methods of treating or preventing acute erythema
US20120082625A1 (en) 2010-09-28 2012-04-05 Michael Graeber Combination treatment for rosacea
JP6030067B2 (ja) * 2010-12-03 2016-11-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的クリーム組成物および使用法
BR112013020770A2 (pt) 2011-02-15 2019-08-27 Allergan, Inc. composições de creme farmacêutico de oximetazolina para tratamento de sintomas de rosácea
CN103796652A (zh) 2011-07-14 2014-05-14 阿勒根公司 羟甲唑啉的凝胶组合物及使用方法

Also Published As

Publication number Publication date
US20200276108A1 (en) 2020-09-03
AU2012217858A1 (en) 2013-09-05
US11541000B2 (en) 2023-01-03
CN103458897A (zh) 2013-12-18
JP6225030B2 (ja) 2017-11-01
CN107007546A (zh) 2017-08-04
EP2675449A1 (en) 2013-12-25
AU2019203993B2 (en) 2020-05-28
EP3578178A1 (en) 2019-12-11
KR102058756B1 (ko) 2020-01-22
RU2648439C2 (ru) 2018-03-26
AU2017202726B2 (en) 2019-03-07
KR20190114010A (ko) 2019-10-08
JP2014505733A (ja) 2014-03-06
KR20140020912A (ko) 2014-02-19
US20140113947A1 (en) 2014-04-24
ES2742273T3 (es) 2020-02-13
BR112013020770A2 (pt) 2019-08-27
EP2675449B1 (en) 2019-04-24
US20190167566A1 (en) 2019-06-06
JP2017066162A (ja) 2017-04-06
US20120208858A1 (en) 2012-08-16
JP6389534B2 (ja) 2018-09-12
AU2017202726A1 (en) 2017-05-18
CA2827373A1 (en) 2012-08-23
EP3578178B1 (en) 2026-04-08
AU2019203993A1 (en) 2019-06-27
WO2012112566A1 (en) 2012-08-23
JP2018193399A (ja) 2018-12-06
RU2013141845A (ru) 2015-03-27

Similar Documents

Publication Publication Date Title
US11541000B2 (en) Pharmaceutical cream compositions of oxymetazoline and methods of use
AU2018229508B2 (en) Pharmaceutical cream compositions comprising oxymetazoline
US20130079379A1 (en) Gel compositions of oxymetazoline and methods of use
HK1192724B (en) Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
HK1192724A (en) Pharmaceutical cream compositions of oxymetazoline for treating symptoms of rosacea
HK1190307B (en) Pharmaceutical cream compositions comprising oxymetazoline

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170127

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250207

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250207